Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Apolipoprotein C3 (apoC3) plays a key role in triglyceride metabolism.
• Inhibition of apoC3 is a potential therapeutic strategy for hypertriglyceridemia.

Purpose of the Study:

• To investigate the effect of apoC3 inhibition using an antisense oligonucleotide (ASO) on intestinal triglyceride secretion.
• To determine if reduced intestinal triglyceride output contributes to the plasma triglyceride-lowering effects of apoC3 ASO therapy.

Main Methods:

• Rats received apoC3 ASO or inactive ASO for 4 weeks.
• Lymphatic triglyceride and apoB48 secretion were measured after intraduodenal lipid administration.
• Intestinal and hepatic apoC3 expression was assessed via quantitative PCR.

Main Results:

• ApoC3 ASO significantly reduced hepatic and intestinal apoC3 mRNA expression and plasma triglyceride levels.
• Intestinal triglyceride secretion into lymph increased by 38% despite apoC3 ASO treatment.
• Lymph apoB48 output, lymph flow, and stool triglyceride levels remained unchanged.

Conclusions:

• ApoC3 ASO effectively lowers plasma triglycerides but paradoxically increases intestinal triglyceride secretion.
• Reduced intestinal triglyceride output is not the mechanism for the plasma triglyceride-lowering effect of apoC3 ASO.
• Further research is needed to elucidate the mechanism behind the observed intestinal effect.